Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacists improve outcomes but often can’t bill for it, making billing parity key to growing services.
|Articles|August 1, 2002
Winning women over
Irene Brewster*, a 31-year-old mother of two who was in her 31st week of pregnancy, woke up one morning and noticed that her calf was abnormally swollen. After a call to her obstetrician, who was out of town, Brewster rounded up her children and drove to the hospital.
Advertisement
Advertisement
Related to this article
Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacy should be treated as a clinical service line, not just a 340B financial workhorse.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say research justifies services and opens doors to limited distribution drugs.
As the pharmacist pipeline tightens, leaders from UC Davis Health, UCSF Health, and Sutter Health say financial sustainability now depends as much on capacity as on cost.
AMCP leaders say PBM reform, new drug pricing models and AI will shape this week’s Nexus meeting in San Diego.
Ty Gluckman, M.D., says missed lipid tests and clinical inertia, not prior authorization, are now the main barriers to reaching LDL goals.
Christine Johnston says biosimilar interchangeability bills, plus 2026 PBM reforms, would force PBMs to justify preferring higher-cost brands.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Heart data in sleep study predicts atrial fibrillation, heart failure years in advance
2
5 things you should know about intismeran, the Moderna-Merck cancer vaccine
3
Ty Gluckman, M.D., on what the new lipid guidelines mean for payers | HSES 2026
4
Christine Johnston on biosimilar interchangeability and PBM formularies
5